Cohort 4+ vs 3 Dose Severe Disease VE with Different Non−Matched Designs

Design	Adjusted	Boost In Prior Q	Start Quarter	n		VE	95% CI
1	N	N	Q2 2022	101313		−5.778	(−7.127,−4.652)
2	Y	N	Q2 2022	101313		−3.587	(−4.552,−2.789)
3	N	Y	Q2 2022	102527		−5.306	(−6.497,−4.304)
4	Y	Y	Q2 2022	102527		−3.349	(−4.216,−2.626)
5	N	N	Q3 2022	82471		−26.641	(−39.353,−17.934)
6	Y	N	Q3 2022	82471		−18.977	(−28.426,−12.562)
7	N	Y	Q3 2022	87227		−8.028	(−10.240,−6.251)
8	Y	Y	Q3 2022	87227		−6.141	(−8.028,−4.649)